Because co-inhibition of CDK12 and P-TEFb decreased the growth of HCT116 cells independently of p53 (Figure 4), we reasoned that the targeting of CDK12 exposed novel vulnerabilities of cancer cells that could be exploited. Here, TP53 is linked to cancer.